Archive for the ‘Business’ Category
RTP oncology startup gears up to launch first product
Wednesday, April 20, 2011, 7:15 pm No Comments | Post a CommentEditor’s note: North Carolina’s Research Triangle is home to hundreds of young companies. Scientists and entrepreneurs started them to develop technologies and medicines for better detection and treatment of diseases. Some of the companies work on innovations that are the result of research done at one of the area’s universities. Others are outgrowths of established companies. CivaTech Oncology, a startup that’s been around since 2006, employs two full-time and three part-time and is about to launch its first product, is one of those young companies.
Much of the furniture in the about 2,500-square-feet that CivaTech occupies at Park Research Center, a 13-building complex in Research Triangle Park, is second-hand. As the company’s two full-time employees, Suzanne Troxler Babcock and Seth Hoedl have important-sounding titles - Babcock is executive chairwoman and Hoedl is chief science officer - but they rely on a team of part-time employees and consultants.
Like many startups, CivaTech operates on a tight budget. Since its inception, the company has raised about $2 million from private investors, most of them live in the RTP area.
But things are about to change, said Babcock.
“We think we’ll look quite different as an organization by the end of this year,” she said.
CivaTech is looking for a partner to start selling its first product, a next-generation alternative to radioactive seeds that have been used for about 20 years to help reduce tumors in the prostate, breast and cervix.
The Food and Drug Administration has already approved the product, called Civa-String, and Babcock said the first prostate cancer patient is expected to get a Civa-String implant this fall.
That would make the start-up a competitor in a growing market already occupied by some large, publicly traded companies.
Brachytherapy products, which is what the radioactive seeds are, generated $240 million in U.S. sales in 2008, according to a 2009 report by Bio-Tech Systems, a market research firm in the healthcare field. But by 2016, the market is projected to increase to about $2 billion in sales.
Radioactive seeds to treat prostate cancer accounted for about half of the 2008 sales, Bio-Tech Systems reported.
The biggest suppliers of the seeds are C.R. Bard, a New Jersey-based company that is publicly traded and reported $2.7 billion in sales last year; Oncura, a division of General Electric; and Theragenics, an Atlanta-based company with about $80 million in annual revenue.
The radioactive seeds are about the size of rice kernels - cylinders made of titanium and filled with radioactive material, iodine-125 or palladium-103. Worldwide, about 15,000 prostate cancer patients receive the seeds every year.
The radioactive seeds have side effects, frequent bathroom visits and sensitivity to many fruits and other foods. But the biggest problem with the seeds is that they can migrate, Hoedl said. About 120 seeds are implanted in a prostate for a therapeutic dose, he said. If one or two of them migrate, they can end up in the patient’s lung or kidney and do damage.
Civa-Strings shouldn’t migrate. They’re cheaper to make, because they require half the radioactive material to deliver the same therapeutic dose, Hoedl said. They dispense the radiation more uniformly and they’re made with palladium-103, an isotope that works more than three times faster than iodine-125.

A Civa-String, filled with palladium-103 and gold markers. The gold helps the doctor find the strip once it is implanted. Courtesy: CivaTech
The strings are flexible plastic tubes about the thickness of an angelhair spaghetti noodle that are loaded with palladium-103 and gold pellets. Depending on the dose prescribed for each patient, they come in lengths from less than an inch to about 2.5 inches. Radiation oncologists place the loaded strings with the same kind of 8-inch-long needle as the seeds.
Instead of about 120 seeds, a prostate cancer patient would require only 20 to 25 of the strings, Hoedl said.
CivaTech worked with the N.C. State University’s nuclear engineering department to make sure the palladium-103 doesn’t leach out.
If the launch happens as planned, Babcock expected to hire four more full-time employees this year.
Meanwhile, development of the next product, a sheet with palladium-103 loaded strips, continues. The sheet is aimed at shrinking cancers in the lung, colon and esophagus. Last year, CivaTech received $200,000 from the National Institutes of Health to work on the sheet.
Offering a hand-up to student entrepreneurs
Tuesday, April 5, 2011, 5:24 pm No Comments | Post a CommentScott Kelly followed a long tradition with Startup Madness, a showcase of entrepreneurship and innovation in North Carolina’s Research Triangle.
Kelly, an investment banker at KeySource Bank who has worked in Internet marketing and sales, recognized the enormous job creation potential of a three-county area dotted with universities - just like economic developers, academics and businessmen did in the 1950s when they established Research Triangle Park on wooded land that was flanked by Duke University in Durham, the University of North Carolina at Chapel Hill and N.C. State University in Raleigh.
Just like the RTP supporters, Kelly focused on Duke, UNC and NCSU students.
Startup Madness, which took place March 31 on the American Tobacco Campus in downtown Durham, introduced student entrepreneurs to the Research Triangle’s investor and business community. The goal, Kelly said, was to encourage innovative young minds to stay and to retain the startup businesses that are born here on university campuses.
“We have the universities. We have young talent, possibly more than anybody else,” Kelly said. “It would be a shame if they leave.”
Startup Madness was the third entrepreneurial showcase Kelly has organized in the past year. The first took place in May 2010, three months after the recession pushed North Carolina’s unemployment rate to 11.4 percent. In the Triangle, more than 8 percent of the labor force was out of work at the time.
Considering that about three-fourths of U.S. jobs tend to be in businesses with fewer than 100 employees, Kelly thought that helping student entrepreneurs start companies in the Triangle would be a good idea to address the unemployment rate.
At Startup Madness, three student entrepreneurs, one each from Duke, UNC and NCSU, pitched business ideas. The crowd picked the most popular idea. The winner, Kelly said, would get lunch with local business leaders and venture capital and angel investors.
The pitches were:
- An infrared glove that monitors blood glucose levels in children with Type 1 diabetes continuously. The glove is worn at night and replaces repeated finger pricks, said Kyle Foti, one of eight NCSU undergraduate students working on a prototype. Currently, children with Type 1 diabetes must be woken several times at night and tested to prevent hyperglycemia, which can damage the brain and organs. The glove is not only more accurate, but it would also wake parents and children only when there’s a problem.
- Unfiltered voice messages from professional athletes that fans can receive on their mobile phones. Gridiron Grunts plans to start with messages from NFL football players and then go on to NASCAR drivers, said Jeb Terry, a UNC business student who spent five years playing football professionally. Revenue would come from subscriptions, Terry said.
- Internet discounts on merchandise that local businesses offer college students. After its launch a few weeks ago Sidewalk already had 1,000 users across Internet platforms, said Brian Laker, a Duke business student. The merchants pay Sidewalk a fee for the services.
And the winner was: The infrared glove to prevent hyperglycemia, the first product being developed by Diagnostic Apparel.
Pest control from spoiled milk
Wednesday, March 9, 2011, 5:21 pm 1 Comment | Post a CommentThis spring, U.S. farmers are planting corn fortified with a new genetic weapon against hungry caterpillars: A chemical that an entomologist in North Carolina’s Research Triangle Park found 18 years ago in a batch of spoiled milk from his refrigerator.
The chemical is a protein that works like a natural insecticide. It is made by a bacterium that lives in the soil.
Bacillus thuringiensis has long been known as a natural pest control. Agricultural chemical giants Monsanto, Dow, Syngenta and BASF have borrowed genetic material from the bacterium to protect crops from insect damage.
But the protein that Greg Warren discovered in the spoiled milk was different from anything that was known or used in agricultural pest control. He tried it on cutworms, caterpillars that chew through the stems of seedlings. It worked.
“They take a bite, they die,” said Warren, a bench-scientist-turned-patent-lawyer at Syngenta’s corporate biotech research hub in RTP.
Genetic engineering, manipulating genetic material in ways that don’t happen naturally, can be as controversial as it is common. Genetic engineering has brought about animals that researchers use to better understand human diseases, animals and plants that produce medicines and agricultural crops that tolerate drought and weed killers, control harmful insects and even produce an extra vitamin.
A year ago, the U.S. Department of Agriculture cleared the genetic trait Warren discovered for commercial use and Syngenta packaged it with other traits in genetically engineered corn seeds that it started selling last fall under the name Viptera.
“It’s a big deal in terms of sustainable pest control,” said Fred Gould, professor of agriculture at N.C. State University. It provides a novel defense against pests that have gotten used to the plants’ old weapons and new pests that moved in once the competition was gone.
The older bacillus thuringiensis pest control trait, also known as the Cry gene, has been around since 1985 and is in nearly 20 percent of all biotech crops.
The rod-shaped bacterium activates the Cry gene at the end of its life. Just before it dies, it makes a spore to produce offspring and an endotoxin in the shape of diamond crystals to ward off pests.
Earlier in its life cycle, when it divides into what looks like strings of beads, bacillus thuringienses also makes chemicals that act as bioinsecticides. They are called vegetative insecticide proteins or VIPs and are more powerful than endotoxins.
In the early 1990s researchers knew very little about VIPs beyond the fact that they existed, Warren said. “It was an area that hadn’t been explored.”
Warren, who in 1989 had joined Ciba-Geigy’s labs in RTP, wanted to find them. He took dozens of samples, of plants, dust and soil, to isolate bacteria, but none produced a chemical that killed cutworms. His managers at Ciba-Geigy and researchers at universities weren’t very hopeful.
They told him, “You’re crazy, you’re not going to find anything,” Warren recalled.
He didn’t listen. In 1993, he tested a sample of spoiled milk he had brought from home and found a bacillus thuringiensis strain in it. When he cultivated the bacteria and fed the liquid they had thrived in to cutworms, the caterpillars died.
“Out of contaminated food, we found a blockbuster product,” Warren said.
So why did it take 18 years to come to market?
“This is a very unique protein that has very unique properties,” Warren said. “It took time to figure out all those properties.”
Also, it didn’t help that the development of the VIP trait coincided with two large mergers, he said. Again and again, he had to convince superiors to continue funding the research.
In 1996, Ciba Geigy and Sandoz merged to become Novartis. Four years later, Novartis and AstraZeneca merged their agricultural business and formed Syngenta. Warren went to law school to become a patent lawyer the same year the second merger happened. Eric Chen, Warren’s successor as the head of Syngenta’s biostress traits group, oversaw the lab work to make the bacterial VIP gene acceptable to the corn plant.
Last year, Syngenta’s VIP trait won an international award for best novel agricultural biotech product and Michael Mack, the Swiss company’s chief executive, said in an interview with BusinessWeek that Viptera provides Syngenta a chance to challenge Monsanto, the market leader in genetically engineered crop seeds.
IBM Leads Country, State in Invention in 2010
Thursday, February 10, 2011, 8:30 am 1 Comment | Post a Comment
Cyber-criminals probe databases in ways that can be predicted and detected. That's the basis of newly patented IBM software that monitors access to databases for suspicious activity and then locks down critical data.
Burglars often act in predictable ways: they lurk in overgrown bushes, come to your door pretending to be service people, or check for unlocked doors. If you witness this kind of behavior outside your house, you’re likely to check your locks and perhaps arm your security system before calling the police.
Cyber-criminals are the same as physical ones, says IBM’s Dave Kaminsky. They probe databases in ways that can be predicted and detected. That’s the basis of U.S. patent no. 7,827,608: software that monitors access to databases for suspicious activity and then locks down critical data, preventing it from being downloaded. It is intended for use at banks, mortgage companies, and other companies that might keep your social security number or other private information in their databases.
Importantly, the software monitors realtime events, acting only if an intrusion appears to be imminent. As Kaminsky says, it would be counterproductive to forestall legitimate attempts to access information (such as for a credit check), just as you don’t want to overreact when someone comes to your house to clean your gutters.
Kaminsky is IBM’s Chief Patent Innovation Architect. Based at RTP, he is not only a frequently patented inventor, but he helps other inventors in the company navigate the “Alice in Wonderland” world of the patent process and contributes to decision-making about which innovations the company should patent. That last is important, because even though IBM received 5,896 patents in 2010, more than any other company, Kaminksy says just a fraction of the company’s eligible innovations go forward in the patent process.
IBM’s RTP site generated 570 patents, and those, combined with patents from Charlotte, made IBM the leading recipient of patents in the state, ahead of Cree, Red Hat, and the leading universities. Most of the patents from RTP are in software. They include a program that routes phone calls to either internet or traditional phone lines to incur cost savings (patent no. 7,710,946, Jim Silwa) and a GPS add-on that gives drivers of hybrid, electric, or other alt-fuel vehicles routing that will lead them to charging stations, thereby reducing their fossil fuel usage (patent no. 7,860,808, Mark Peters). Then there are hundreds more inventions that may not resonate with consumers, like a new caching algorithm, Kaminsky says, but that make our lives easier nonetheless.

Almost 100 years ago, IBM received its first patent. In 2010, it received 5,896, more than any other company
IBM encourages staff members to generate patentable ideas, Kaminsky says, through a financial incentive program and through career advancement: people who contribute to the intellectual property of the organization are likely to advance.
Contrary to the stereotype of the inventor as a lonely figure, most patents achieved at IBM come from ad hoc groups. Kaminsky led a team of four software engineers on the online security project, which took less than six months to complete but almost four years to patent. Ideas come from clients and from the inventors themselves, sometimes through conversations with collaborators and sometimes through “Aha” moments when people think of ways in which technology could solve a problem.
This was the 18th consecutive year that IBM has led the list of U.S. patents received. According to a company press release, “more than 7,000 IBM inventors residing in 46 different U.S. states and 29 countries generated the company’s record-breaking 2010 patent tally.”
Epic’s Bulletstorm demo hits Xbox Live, PSN
Wednesday, January 26, 2011, 12:23 pm No Comments | Post a CommentCary-based Epic Games released its free Bulletstorm demo for Xbox Live and the PlayStation Network Tuesday, about a month before it hits store shelves.
The sci-fi action-shooter — a collaboration between Epic, People Can Fly and Electronic Arts — follows space pirate Grayson Hunt as he blasts his way through a paradise planet filled with destruction. Central to the gameplay are bonus points for “killing with skill” — finding creative ways to dispatch your enemies using combinations of outlandish weapons, the deadly environment and an energy whip.
Did I mention it was rated “M” for mature?
The demo is only about seven minutes long (six if you make the target time), but it’s packed with enough bullets and body parts to satiate most fans of first-person shooters.
I think the full game will too. At least for a little while. Read more…
Activate3D wants to make your virtual movement more real
Friday, January 21, 2011, 1:11 pm No Comments | Post a CommentThe lights in the conference room before him are dimly lit, but Dan Amerson is still scanning faces in the crowd as he paces excitedly, silhouetted by the glow of the projector screen behind him. He’s explaining to the audience, matter-of-factly, about the critical elements missing from the motion gaming industry today.
For more than three decades, video games offered players an effective method of digitizing their actions and translating them to on-screen motion. With dials, buttons and joysticks, gamers could manipulate their virtual worlds without much effort. It was tactile. Simple. And particularly with next-generation consoles, it granted the ability to make and break contact with objects in the game with a twist, mash or thrust.
But what took off with the Nintendo Wii in 2006 and continued this holiday season with the Xbox Kinect and Playstation Move was a desire for a more active form of interaction — motion.
That’s both a problem and an opportunity for programmers like Amerson, vice president of engineering for middleware developer Activate3D. As it turns out, computers are downright terrible at figuring out what you’re trying to do when you don’t have buttons.
But Amerson’s plan is to equip games to recognize that subtlety, using what his company calls intention recognition and synthesis.
“A lot of motion games out there can take your motion and they can put it on-screen, but what they can’t do is let you grab onto that object in the world and let you do something meaningful,” Amerson told the crowd at RTP Headquarters in Durham, N.C., Dec. 8.
If his company is successful in bringing its technology to market, Amerson believes it will change the way people engage virtual environments.
“The Playstation 3 and the Xbox 360 have not changed since they came out, yet everyone wants to have a bigger, better, badder game. So how do we do that? Well, we have to write better code, we have to make our artists smarter, give them better tools, come up with new tricks,” Amerson said.
HISTORY OF FAILURE
Motion controlled games aren’t particularly new. Long before the Wii had consumers lining up outside stores in the cold, Mattel’s Power Glove for the Nintendo Entertainment System tracked course hand gestures in 1989. Despite grossing $88 million, it underwhelmed consumers.
Sega released its Activator peripheral in 1993, telling players in an elaborate four-minute instructional video how they were “pioneers on the interactive frontier.” The video also warned against placing the octagonal device, which worked when users broke an infrared beam, under overhead light sources or “metallic or mirrored ceilings.” It never caught on.
But as gaming systems became more powerful, peripherals manufacturers started getting the formula right. As a precursor to the more modern movement-based controllers, the Logitech EyeToy, released for the Sony PlayStation 2 before the holidays in 2003, attempted to capture motion by placing the player’s image on-screen using a camera. It sold 400,000 units in North America alone by the end of the year.
“People seem to have forgotten that there were games controlled solely by camera back on the PlayStation 2,” Amerson said. “As the technology moves forward, we’re going to get increasingly more accurate, better fidelity, interesting new combinations of the technology. We’ve now got the ability to use not just course motion, but actually some very precise motion.”
And that’s where devices like the Move and Kinect can succeed where others have failed, according to Michael Young, an associate professor of computer science at N.C. State who taught Amerson as an undergraduate (full disclosure: I’m employed by N.C. State as a journalism adviser).
“The real principle challenge is to correctly map a player’s intent to how they play the game,” Young, who teachers courses in video game design, said. “The greater the connection between the choices of the player and the feedback of the game, the greater the acceptance of the choices you have.”
But to cement that connection, Amerson says the Kinect and Move will need a little help from his company’s technology.
“Taking input data, taking someone cavorting in front of a camera and putting it on-screen is of limited interest. You’ll go do it sometime in your life and it’ll be fun. You’ll have a good time,” he said. “But 15 minutes later, you’ll realize that’s all there is to it.”
REDUCING THE NOISE
Booting up a small camera at the front of the dark Durham conference room, a miniaturized image of Amerson pops up in the corner of the screen behind him. Looming larger on the screen over the 6-foot-2-inch programmer’s shoulder is a teenaged avatar sporting a long-sleeved shirt and blue jeans, looking out over a vibrant playground.

Dan Amerson, from Activate3D, demonstrates his company's Intelligent Character Motion technology at RTP Headquarters Dec. 8. | Photo by Tyler Dukes
The kid on-screen mimics Amerson’s motions until he approaches a set of virtual monkey bars. Miming a leap without ever leaving the ground, Amerson closes his hands as his on-screen persona grasps the bars and hangs free, ignoring the real Amerson’s legs rooted firmly on the conference room floor.
Actions like these aren’t easy for a program to understand, especially given the limited data from one camera.
Take grabbing things, for instance. The image of an opening and closing human hand can appear radically different depending on how it’s positioned. And absent a controller, that image is all the program has to go on.
So Activate3D’s Intelligent Character Motion software helps it make an educated guess. By processing dozens of images of open and closed hands, the system builds a mathematical model. The team then pipes in live video of their hands while the system guesses if they’re open, and humans make corrections along the way.
The software also recognizes what the player intends to do — jumping for example — without literal action. This could help games overcome an obvious constraint: there are only so many fun things you can do from inside your house.
“If I’m in front of a camera in my living room and I start walking, I quickly run into a physical limitation of gameplay when I knock over the camera or run smack into my TV,” Amerson said.
Translating real-world motion into virtual action also runs the risk of falling into the “uncanny valley,” where unnatural movement of almost-lifelike 3D animation actually grosses us out. ICM avoids that gut reaction by augmenting the player’s motion and removing irrelevant input — like the position of Amerson’s legs when his avatar is hanging in mid-air. By filtering that signal, the program allows virtual gravity to take effect, letting the legs swing and the shoulders rotate naturally.
“I can break the rules of the virtual world very easily,” Amerson said. “We want to take all this into account and augment that — make you look like you’re doing what’s happening there — and then blend all that together, make it fit the environment, fit the physics and make it believable to you.”
By staying away from the uncanny valley, Young said players will get a more immersive experience when they step into the “magic circle” of a video game.
“The relationship between the body and avatar, by default, is one to one,” Young said. “When it doesn’t happen, it pulls us out of the game.”
Although Amerson said there will always be great games that map motion literally, augmentation opens new possibilities for moving gaming forward.
“Give me a Kung Fu game. I can mimic those motions, I could pretend that I’m Jackie Chan,” he said. “But wouldn’t it be really awesome if, in my living room, I can pretend to be Jackie Chan and on TV see my avatar move with the grace and the fluidity and the expertise of Jackie Chan or Jet Li?”
And he said helping players inhabit actions that aren’t their own is what motion gaming needs to move from amusing to memorable.
“The best games give you 80 percent of the experience with 10 percent of the effort,” he said. “I think ultimately, that’s what game designers are trying to do — giving you as big and as bold an experience as possible with a low barrier of entry so it stays fun.”
Tyler Dukes is a freelance science writer and full-time journalism adviser at North Carolina State University. Follow him on Twitter as @mtdukes.
Engineering for Better Wastewater Treatment Results
Sunday, December 26, 2010, 3:02 pm 1 Comment | Post a CommentA few weeks ago, I reported on water quality expert Kenneth Reckhow’s concern that we will be unable to achieve water quality standards set by states in response to the Clean Water Act. Municipal water treatment plants have been improved “to the limits of technology,” he said, and additional cleanup was going to have to happen with somewhat unlikely changes like limiting development, changing farming practices, and prohibiting lawn fertilizers.
Last week, I had the opportunity to discuss the challenges of cleaning wastewater from the perspective of an entrepreneur who has been working with municipalities and industry to improve treatment plant performance. Wayne Flournoy is cofounder and president of Entex Technologies, a Chapel Hill company that designs systems for upgrading wastewater treatment plants or for new plants. Read more…
Unleashing the power of 1100 suns
Friday, December 17, 2010, 2:19 pm No Comments | Post a CommentA year or so ago, Joseph Carr found himself on an elevator with a man wearing a Siemens polo shirt. Having once worked for a division of Siemens, Carr introduced himself as the CEO of Semprius, Inc., a company that makes very high-efficiency solar modules. At the end of a fourteen-floor ascent, the two men exchanged business cards. Within months, Semprius and Siemens announced a joint development agreement.
Yes, a true “elevator pitch” success story.
Yap, Inc., Brings Us the Speech Cloud
Friday, November 5, 2010, 8:37 am 1 Comment | Post a CommentTechnology and language are strange and occasionally wonderful bedfellows. The same field that gave us 802.11b to describe a common household wireless standard is also capable of whimsical and clever trademarks. (Quick: when I say “blackberry,” do you envision a smart phone or an old-fashioned fruit?)
One of the best flights of fancy that has come from the wireless revolution is the Cloud. Loosely speaking, the cloud is the Internet—all of those computers out there that connect us in the world wide web. But cloud computing also refers to applications and sometimes data that reside “out there” rather than on your own computer. It’s rather soothing to think about all of those bits of code bouncing around the stratosphere on a cumulus mattress rather than residing in earthbound bunkers of supercomputers.
I was charmed, therefore, when reading up on Yap, Inc., to learn about the Speech Cloud. Yap provides software-processed (rather than human-processed) speech recognition services, largely via partners like Microsoft and Sprint and other phone carriers. Voice mails, conference calls, and other bits of dictation are transported to Yap’s Speech Cloud and rendered into text by software and returned to the customer’s computer or device.
On the cutting edge: Three women in translational research
Wednesday, October 27, 2010, 9:16 pm 1 Comment | Post a CommentLarge pharmaceutical companies already leave much of the translational research to biotech companies and startups. But now, turning an idea into a potential product is gaining importance at U.S. medical schools as more and more university scientists are taking on the development of disease treatments and preventions.
In North Carolina, researchers at Wake Forest University are about to test a novel vaccine booster in healthy volunteers. The New England Journal of Medicine this month published the results of the first clinical trial of a therapy developed at the University of North Carolina at Chapel Hill to replace a defective gene that causes Duchenne’s muscular dystrophy. And Duke University researchers have come up with treatments for two rare diseases, Krabbe disease and Pompe disease, and are working on three more.
The three scientists that the Raleigh-based Carolinas Chapter of The Indus Entrepreneurs invited to its life science panel discussion Tuesday at Brier Creek Country Club reflected not only this research & development shift, but as women they also succeeded in a male-dominated field.
One of the panel members was Dr. Priya Kishnani, a Duke pediatrician and geneticist, who was instrumental in developing Myozyme, a Pompe disease treatment that was approved in 2006 and is marketed by Genzyme.
Kishnani was joined by Prabhavathi Fernandes, chief executive of Cempra Pharmaceuticals, and Christy Shaffer, former chief executive of Inspire Pharmaceuticals.
Research Triangle Park was established to bring together academia and industry and develop research-based products. In that respect, Cempra, a 4-year-old Chapel Hill startup that has raised $60 million in venture capital to develop new antibiotics, and Inspire, a publicly traded Durham company with about $100 million in annual revenue, are driving forces in the home-grown life cycle of drug development.
The trio talked about what inspires them, whether they believe in an entrepreneurial gene and what’s unique about translational research in RTP. They also fielded questions from the audience, including one from Leslie Alexandre, former chief executive of the N.C. Biotechnology Center, on pricing of new medicines in the face of rising health care costs. Read more…
















